Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan/Theravance’s Yupelri Will Launch Late This Year To Address COPD Niche

Executive Summary

Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive pulmonary disease.

You may also be interested in...



Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback

The Phase III failure of ampreloxetine in nOH followed disappointing Phase IIb data for izencitinib in ulcerative colitis in August. Theravance narrows focus to respiratory disease, including label expansions for Yupelri.

Earnings Roundup: Specialty/Smaller Biopharmas See Modest Hit From Pandemic

First quarter financials and COVID-19 impacts from Bausch, Neurocrine, Theravance, Ironwood, Rigel.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel